Pliant Therapeutics, Inc. has announced the initiation of a new at-the-market offering program, allowing the company to sell shares of its common stock with an aggregate offering price of up to $50 million. This decision follows the termination of a previous sales agreement with Cantor Fitzgerald & Co., which had been in place since July 2021 but had not resulted in any sales prior to its termination. The new sales agreement, effective March 27, 2026, was established with Leerink Partners LLC as the sales agent. The company is not subject to any termination penalties related to the previous agreement, indicating a strategic shift in its financing approach. This move is expected to enhance liquidity and provide the company with additional capital to support its operational needs and strategic initiatives. Investors may view this as a positive development, as it reflects the company's proactive approach to managing its capital structure and funding its growth initiatives.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.